CA
NZ
UK
AU
IND
US
…
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Oculis Holding AG is a clinical-stage ophthalmology company listed on NASDAQ that develops topical therapies for retinal and inflammatory eye diseases. Long-term growth may be supported by successful clinical outcomes, regulatory approvals for non‑invasive ocular treatments and partnerships to commercialize its formulation and delivery approach, which could appeal to investors seeking exposure to unmet needs in eye care.
Key risks include clinical and regulatory failure, absence of predictable product revenue, the need for additional financing and intense competition from established ophthalmology firms.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -38.64M | -18.52M | -14.79M |
| Net income | -38.70M | -18.55M | -14.87M |
| Selling general administrative | 6.74M | 4.10M | 3.52M |
| Reconciled depreciation | 0.30M | 0.23M | 0.23M |
| Ebit | -32.25M | -13.21M | -12.32M |
| Ebitda | -31.95M | -12.98M | -12.10M |
| Depreciation and amortization | 0.30M | 0.23M | 0.23M |
| Operating income | -32.38M | -13.23M | -12.34M |
| Other operating expenses | 32.38M | 13.23M | 12.34M |
| Interest expense | 6.44M | 5.12M | 2.63M |
| Tax provision | 0.06M | 0.03M | 0.08M |
| Interest income | 0.13M | 0.02M | 0.01M |
| Net interest income | -6.32M | -5.10M | -2.62M |
| Income tax expense | 0.06M | 0.03M | 0.08M |
| Total revenue | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 32.38M | 13.23M | 12.34M |
| Total other income expense net | 0.05M | -0.19M | 0.16M |
| Net income from continuing ops | -38.70M | -18.55M | -14.87M |
| Net income applicable to common shares | - | - | -14.87M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 114.35M | 37.06M | 58.04M | 16.38M |
| Intangible assets | 12.21M | 12.21M | - | - |
| Other current assets | 9.36M | - | - | 0.00M |
| Total liab | 20.62M | 135.05M | 119.00M | 60.04M |
| Total stockholder equity | 93.73M | -97.99M | -60.95M | -43.65M |
| Other current liab | 5.37M | 8.01M | 3.04M | 3.36M |
| Common stock | 0.37M | 0.34M | 0.34M | 0.30M |
| Capital stock | 0.37M | 0.34M | 0.34M | 0.30M |
| Retained earnings | -199.78M | -110.98M | -72.28M | -53.73M |
| Other liab | - | 0.09M | 0.86M | - |
| Other assets | - | - | 0.05M | -0.00M |
| Cash | 38.33M | 19.79M | 46.28M | 4.95M |
| Total current liabilities | 19.09M | 12.02M | 4.06M | 4.34M |
| Current deferred revenue | 5.95M | 8.01M | - | 3.37M |
| Net debt | -37.72M | 103.30M | 68.00M | 49.86M |
| Short term debt | 0.17M | 0.14M | 0.19M | 0.19M |
| Short long term debt total | 0.60M | 123.08M | 114.27M | 54.81M |
| Other stockholder equity | 294.54M | 13.21M | 12.30M | 11.15M |
| Property plant equipment | - | 1.12M | - | - |
| Total current assets | 101.02M | 23.66M | 47.98M | 6.16M |
| Long term investments | - | 0.05M | 0.05M | 0.05M |
| Net tangible assets | - | - | -69.68M | - |
| Short term investments | 53.32M | - | - | - |
| Net receivables | 1.20M | 1.08M | 0.91M | 1.14M |
| Long term debt | - | 122.45M | 113.50M | 53.98M |
| Inventory | -1.20M | - | - | 0.07M |
| Accounts payable | 7.60M | 3.87M | 0.82M | 0.79M |
| Accumulated other comprehensive income | -1.40M | -0.56M | -1.31M | -1.37M |
| Non currrent assets other | 0.09M | - | -0.00M | - |
| Non current assets total | 13.34M | 13.40M | 10.06M | 10.22M |
| Capital lease obligations | 0.60M | 0.63M | 0.77M | 0.83M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -3.55M | -0.03M | -0.02M |
| Change to liabilities | 0.00M | 0.03M | -0.65M |
| Total cashflows from investing activities | -3.55M | -3.55M | -3.55M |
| Net borrowings | -0.16M | -0.16M | -0.10M |
| Total cash from financing activities | 1.71M | 55.19M | 4.86M |
| Change to operating activities | 2.96M | 2.96M | 2.96M |
| Net income | -38.64M | -18.52M | -14.79M |
| Change in cash | -26.49M | 41.33M | -7.20M |
| Begin period cash flow | 46.28M | 4.95M | 12.15M |
| End period cash flow | 19.79M | 46.28M | 4.95M |
| Total cash from operating activities | -25.07M | -13.82M | -12.03M |
| Issuance of capital stock | 2.15M | 56.10M | 5.03M |
| Depreciation | 0.30M | 0.23M | 0.23M |
| Change to account receivables | - | 0.03M | 0.01M |
| Other cashflows from financing activities | 1.75M | 55.29M | 4.96M |
| Change to netincome | - | 5.28M | 3.07M |
| Capital expenditures | 3.55M | 0.03M | 0.02M |
| Change in working capital | 6.00M | -0.79M | -0.45M |
| Stock based compensation | 0.80M | 0.33M | 0.33M |
| Other non cash items | 6.47M | 4.93M | 2.66M |
| Free cash flow | -28.62M | -13.85M | -12.05M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG Ordinary shares |
-0.08 1.04% |
7.63 | 70.08 | - | 496.20 | 4.29 | -3.90 |
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
| Name | Title | Year Born |
|---|---|---|
| Dr. Riad Sherif M.B.A., M.D. | CEO & Director | 1968 |
| Ms. Sylvia Cheung | Chief Financial Officer | 1975 |
| Mr. Weibo Ding | Global COO & GM of China | 1971 |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | NA |
| Ms. Virginia R. Dean | Chief Human Resources Officer | 1967 |
| Dr. Bastian Dehmel M.D. | Chief Development Officer | 1971 |
| Mr. Páll Ragnar Jóhannesson | Chief Business Officer | 1982 |
| Ms. Rebecca Weil | Chief Commercial Officer | NA |
| Dr. Snehal Shah Pharm.D. | President of Research & Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...